Medivation Inc. and partner Astellas Pharma Inc. started a Phase II trial of an experimental prostate cancer treatment, the fourth study involving the drug.
The mid-stage study of the drug, MDV-3100, ultimately will enroll about 60 patients in Europe, San Francisco-based Medivation (NASDAQ: MDVN) said Monday. It will test the drug, taken once a day orally for 24 weeks, as the first hormonal treatment for patients with early-stage prostate cancer.
No comments:
Post a Comment